Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that data from the Company's Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas.

Abstracts will be available on the meeting website today, February 3, 2023.

Presentation Details: Session Date & Time: Sunday, February 26th at 9:45 am - 10:45 am CT (10:45 am ET - 11:45 am ET)

Poster No. 308: Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria

Presenting Author: Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charite - Universitatsmedizin in Berlin

Data included in the abstract are through May 2022. New data will be presented at the AAAAI meeting and will include the following:

Data through 24 weeks for Cohorts 1-3 (0.5, 1.5 and 3.0 mg/kg doses)

Data through 20 weeks for Cohort 4 (4.5 mg/kg dose); 6 of 9 patients available at this timepoint as of the data cut-off date

Webcast and Conference Call

The Company will host a webcast presentation of the data on Sunday, February 26th at 4:00 pm CT (5:00 pm ET). The event will be webcast live and can be accessed by going to the 'Events & Presentations' page under the 'Investors & Media' section of the Celldex Therapeutics website at www.celldex.com.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Contact:

Sarah Cavanaugh

Tel: (508) 864-8337

Email: scavanaugh@celldex.com

(C) 2023 Electronic News Publishing, source ENP Newswire